Redwood Group International (RDWD)

[snowcloud]

NEWS --

DANVILLE, CA, Mar 08, 2010 (MARKETWIRE via COMTEX) -- S3 Investment Company,
Inc. (PINKSHEETS: SIVC) today announced that the c ompany's Redwood Medical
subsidiary, which distributes Western medical technologies and products into the
China market, is currently working on additional State Food and Drug
Administration (SFDA) approvals for the first product it has signed to
distribute in China.

Redwood Medical has entered into an exclusive distribution agreement with Abaxis
Inc., a U.S.-based medical products company manufacturing point-of-care blood
analysis systems for the China market, for distribution of its Piccolo xpress
testing device. The Piccolo xpress product has already received SFDA approval,
and under terms of its agreement with Abaxis, Redwood Medical will distribute
the Piccolo xpress device and its disposable discs throughout China. The
additional SFDA approval is being pursued for the reagents associated with the
Piccolo xpress disposable discs.

Redwood Medical was formed in 2009 to meet the increased demand for the best
available medica l technologies for a growing number of hospital and clinics in
China.

"As we continue to focus on the business of Redwood Capital subsidiary,
specifically the close of current client transactions and the signing of new
clients, our Redwood Medical staff is working with Abaxis to achieve SFDA
approvals on the reagents for the Piccolo xpress. This product has tremendous
potential in the China market, and we look forward to the additional regulatory
approval so that Redwood Medical can implement the most productive distribution
program possible," commented S3 Investment Company Chairman and CEO Jim Bickel.

To sign up to receive information by email directly from S3 Investment Company
when new press releases, investor newsletters, SEC filings or other information
is disclosed, please visit http://www.s3investments.com/investors/.

About S3 Investment Company, Inc. S3 Investment Company, Inc.
(http://www.s3investments.com) and its Redwood Group International subsidiary
are focused on facilitating the success of two subsidiaries operating in the
China market. Redwood Capital, Inc. assists private Chinese companies in
accessing the North American capital markets by utilizing a network of
investment banking relationships to achieve reverse merger transactions. For
more information, please visit http://www.redwoodcapinc.com. Redwood Medical,
Inc. assists companies seeking to import and distribute Western medical
technologies and products into the China market.

Any statements contained herein related to future events are forward-looking
statements and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned not to place
undue reliance on forward-looking statements. S3 Investment Company, Inc.
undertakes no obligation to update any such statements to reflect actual events.





Co ntacts

For S3 Investment Company

Gemini Financial Communications, Inc.

951-200-4107

Email Contact





SOURCE: S3 Investment Company




CONTACT: http://www2.marketwire.com/mw/emailprcntct?id=90782CDA0EF803B4




Copyright 2010 Marketwire, Inc., All rights reserved.

-0-




SUBJECT CODE: Financial Services:Commercial and Investment Banking

Financial Services:Venture Capital

Manufacturing and Production:Machinery and Tools

Pharmaceuticals and Biote ch:Equipment and Supplies

Medical and Healthcare:Medical Devices

Medical and Healthcare:Surgery and Treatments

Medical and Healthcare:Healthcare